Class: Thiazide diuretic
- Tablets 12.5 mg
- Tablets 25 mg
- Tablets 50 mg
- Capsules 12.5 mg
Enhances excretion of sodium, chloride, and water by interfering with transport of sodium ions across renal tubular epithelium.
Bioavailability is 65% to 75%, C max is 70 to 490 ng/mL (dose dependent), and T max is 1 to 5 h. Food reduces the bioavailability 10% and the C max 20% and increases the T max from 1.6 to 2.9 h. Plasma concentrations are linearly related to administered dose.
Protein binding is 40% to 68% and crosses the placenta but not the blood brain barrier. It is also excreted in breast milk.
Hydrochlorothiazide is not metabolized.
Hydrochlorothiazide is eliminated primarily by renal pathways (as unchanged by the kidneys; 55% to 77% of the administered dose appears in urine with more than 95% of the absorbed dose excreted in urine unchanged). Plasma half-life is 5.6 to 14.8 h.
The time to peak effect is approximately 4 h.
Hydrochlorothiazide activity may persist for up to 24 h.
Special PopulationsRenal Function Impairment
Hydrochlorothiazide plasma concentration is increased and the half-life is prolonged.
Indications and Usage
Adjunctive therapy for edema associated with CHF, hepatic cirrhosis, renal function impairment, and corticosteroid and estrogen therapy; treatment of hypertension.
Therapy for nephrogenic diabetes insipidus.
Hypersensitivity to thiazides, related diuretics, or sulfonamide-derived drugs; anuria; renal decompensation.
Dosage and AdministrationDiuresis (tablets only)
Children (6 mo to 12 y of age)
PO 1 to 2 mg/kg/day in single or 2 divided doses. Max dose for children 2 to 12 y of age is 100 mg/day; for 6 mo to 2 y of age is 37.5 mg/day.Edema (tablets only)
PO 25 to 100 mg/day as a single or divided dose.Hypertension
PO 25 to 50 mg/day as a single dose or 2 divided doses.Children (6 mo to 12 y of age)
PO 1 to 2 mg/kg/day in a single dose or 2 divided doses. Max dose for children 2 to 12 y of age is 100 mg/day; for 6 mo to 2 y of age is 37.5 mg/day.Infants (younger than 6 mo)
PO Doses up to 3 mg/kg/day in 2 divided doses may be required.Capsules Adults
PO 12.5 mg daily (max, 50 mg/day) given alone or in combination with other antihypertensives.
Store tablets in tightly closed container at 15° to 30°C (59° to 86°F).
Drug InteractionsBile acid sequestrants
May reduce thiazide absorption; give thiazide at least 2 h before resin.Diazoxide
May cause hyperglycemia.Digitalis glycosides
Diuretic-induced hypokalemia and hypomagnesemia may precipitate digitalis-induced arrhythmias.Insulin sulfonylureas
May decrease hypoglycemic effect of sulfonylureas. May need to increase dosage of sulfonylureas or insulin.Lithium
May decrease renal excretion of lithium.Loop diuretics
Synergistic effects may result in profound diuresis and serious electrolyte abnormalities.
Laboratory Test Interactions
May decrease serum protein-bound iodine levels without signs of thyroid disturbance. May cause diagnostic interference of serum electrolyte levels, blood and urine glucose levels, serum bilirubin levels, and serum uric acid levels. May increase serum magnesium levels in uremic patients. May cause increased concentrations of total serum cholesterol, total triglycerides, and LDL.
Dizziness, headache, insomnia, light-headedness, paresthesias, restlessness, vertigo, weakness.
Alopecia, erythema multiforme, exfoliative dermatitis, necrotizing angiitis (vasculitis and cutaneous vasculitis), photosensitivity, purpura, rash, Stevens-Johnson syndrome, TEN, urticaria.
Blurred vision, xanthopsia (yellow vision).
Abdominal pain or cramping, anorexia, bloating, constipation, diarrhea, gastric irritation, nausea, pancreatitis, sialadenitis, vomiting.
Impotence, interstitial nephritis, reduced libido.
Agranulocytosis, aplastic or hypoplastic anemia, hemolytic anemia, leukopenia, thrombocytopenia.
Electrolyte imbalance, glycosuria, hyperglycemia, hyperuricemia.
Pneumonitis, pulmonary edema, respiratory distress.
Anaphylactic reactions, fever, muscle cramp or spasm.
Category B .
Excreted in breast milk.
Safety and efficacy have not been established in controlled clinical studies.
May occur in patients with or without history of allergy or bronchial asthma; cross-sensitivity with sulfonamides may also occur.
May precipitate azotemia; use with caution.
Minor alterations of fluid and electrolyte balance may precipitate hepatic coma; use with caution.
Exacerbation or activation may occur.
May enhance antihypertensive effects.
Anuria, confusion, cramps of calf muscles, dizziness, electrolyte abnormalities, lethargy, nausea, potassium deficiency, orthostatic or general hypotension, polyuria, shock, syncope, tachycardia, thirst, vomiting, weakness.
- Instruct patient to take medication early in day with food or milk.
- Instruct patient to monitor weight daily.
- Advise patient to avoid exposure to sunlight and to use sunblock or wear protective clothing to avoid photosensitivity reaction.
- Instruct diabetic patients to report increased levels of blood glucose to health care provider.
- Caution patient to avoid intake of alcoholic beverages.
- Caution patient to rise slowly from lying or sitting position and to lie down if blurred vision or dizziness occurs.
- Tell patient to report these symptoms to health care provider: blurred vision, decrease in urinary output, dizziness, GI disturbances, jaundice, muscle cramps, nausea, weakness.
- Instruct patient to drink 2 to 3 L of fluids daily unless advised otherwise by health care provider.
- Advise patient that drug may cause dizziness and blurred vision and to use caution while driving or performing other tasks requiring mental alertness.
- Tell patient that therapeutic effect may require 2 to 3 wk.
Copyright © 2009 Wolters Kluwer Health.
More Hydrochlorothiazide resources
- Hydrochlorothiazide Prescribing Information (FDA)
- Hydrochlorothiazide Monograph (AHFS DI)
- hydrochlorothiazide Advanced Consumer (Micromedex) - Includes Dosage Information
- hydrochlorothiazide Concise Consumer Information (Cerner Multum)
- hydrochlorothiazide MedFacts Consumer Leaflet (Wolters Kluwer)
- Esidrix Prescribing Information (FDA)
- Microzide Prescribing Information (FDA)
- Microzide MedFacts Consumer Leaflet (Wolters Kluwer)